SCHEMBL6038688

SCHEMBL6038688

Cc1ccc(S(=O)(=O)Nc2nccnc2OCCN2CCOCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.48
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
HIF1A Q16665 1/20 0.47
GAA P10253 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
USP2 O75604 1/20 0.46
MAPT P10636 1/20 0.46
BRD4 O60885 1/20 0.45
EPHX2 P34913 1/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039464 0.89 MBTD1 (0.49) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL6038556 0.85 CCR4 (0.54) RAB9AALDH1A1KMT2A
SCHEMBL6038531 0.84 MBTD1 (0.54) MEN1KMT2A
SCHEMBL6038901 0.84 MEN1 (0.54) RAB9AALDH1A1LMNAHIF1AGAA
SCHEMBL6038473 0.77 MEN1 (0.46) ALDH1A1LMNAGAAMEN1KMT2A
SCHEMBL6038633 0.77 KMT2A (0.46) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL6038730 0.77 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6039178 0.77 MEN1 (0.49) ALDH1A1LMNAGAAMEN1KMT2A
SCHEMBL6038954 0.75 KMT2A (0.50) ALDH1A1LMNAMEN1KMT2ACA12
SCHEMBL6038854 0.75 MEN1 (0.47) ALDH1A1LMNAGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 RAB9A 2005/4885ALDH1A1 2902/4885LMNA 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.